ORG-25935

ORG-25935 is a drug that acts as a serotonin reuptake inhibitor, and was developed for the treatment of depression and anxiety disorders. It was developed by Organon International, a pharmaceutical company based in the Netherlands.

History

ORG-25935 was first synthesized by Organon International in the early 2000s. The drug was developed as a potential treatment for depression and anxiety disorders, due to its ability to inhibit the reuptake of serotonin, a neurotransmitter that is often imbalanced in individuals with these conditions.

Mechanism of Action

ORG-25935 works by inhibiting the reuptake of serotonin, a neurotransmitter that is involved in mood regulation. By preventing the reuptake of serotonin, ORG-25935 increases the amount of serotonin available in the brain, which can help to alleviate symptoms of depression and anxiety.

Clinical Trials

Clinical trials for ORG-25935 were conducted in the mid-2000s. However, the drug did not progress beyond Phase II trials, and its development was discontinued.

See Also

• Organon International
• Serotonin reuptake inhibitor
• Depression
• Anxiety disorders

References

<references />

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

ORG-25935

• 
  Org 25935